SRR1500405
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.434
- SPERMATOGENESIS+0.222
- ANGIOGENESIS+0.213
- PANCREAS_BETA_CELLS+0.200
- COAGULATION+0.192
- APICAL_SURFACE+0.171
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.168
- MYOGENESIS+0.167
- ALLOGRAFT_REJECTION+0.114
- INFLAMMATORY_RESPONSE+0.054
Top 10 suppressed
- MYC_TARGETS_V1-0.606
- MTORC1_SIGNALING-0.560
- MYC_TARGETS_V2-0.556
- PROTEIN_SECRETION-0.550
- UNFOLDED_PROTEIN_RESPONSE-0.543
- DNA_REPAIR-0.531
- OXIDATIVE_PHOSPHORYLATION-0.493
- ANDROGEN_RESPONSE-0.424
- CHOLESTEROL_HOMEOSTASIS-0.419
- E2F_TARGETS-0.417
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1348861 | GTEX | — | 0.988 |
| 2 | SRR1451964 | GTEX | — | 0.979 |
| 3 | SRR1474886 | GTEX | — | 0.973 |
| 4 | SRR1336006 | GTEX | — | 0.971 |
| 5 | SRR1340301 | GTEX | — | 0.962 |
| 6 | SRR1419714 | GTEX | — | 0.961 |
| 7 | BS_0X9EGHY2 | low-grade glioma | — | 0.960 |
| 8 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.960 |
| 9 | MDT-AP-1143 | Med | Medulloblastoma | 0.958 |
| 10 | MNG1118 | — | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.434 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.222 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.213 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| COAGULATION | 0.192 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.171 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.168 | Inavolisib | — uncovered |
| MYOGENESIS | 0.167 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.114 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.054 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.051 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.044 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.031 | Inavolisib | — uncovered |